tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 145 are a BUY (96.67%), 4 are a HOLD (2.67%), 1 are a SELL (0.67%).
Analyst Chad Messer works with a stock forecast success ratio of 39.38% fulfilled within 158.1 days on average. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 261 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on GMDA, Gamida Cell Ltd at 20-Apr-2023.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
30
$2.3 (8.30%)
32
1 months 26 days ago
3/3 (100%)
$-2.99 (-9.06%)
224
Hold
28
$0.3 (1.08%)
32
5 months 15 days ago
6/6 (100%)
$5.51 (24.50%)
192
Buy
42
$14.3 (51.62%)
67
9 months 22 days ago
5/12 (41.67%)
$13.87 (49.31%)
213
Buy
38
$10.3 (37.18%)
40
9 months 22 days ago
0/4 (0%)
$9.87 (35.09%)
Buy
37
$9.3 (33.57%)
33
1 years 8 months 13 days ago
6/11 (54.55%)
$7.26 (24.41%)
69
What Year was the first public recommendation made by Chad Messer?
